PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO

(2015) David E. Reuss et al.   ACTA NEUROPATHOLOGICA

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas

(2015) Adriana Olar et al.   ACTA NEUROPATHOLOGICA

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

(2015) Michael Weller et al.   ACTA NEUROPATHOLOGICA

Clinical impact of molecular biomarkers in gliomas

(2015) Tali Siegal   JOURNAL OF CLINICAL NEUROSCIENCE

Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials

(2015) Johan M. Kros et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene of the month:PIK3CA

(2015) K Lai et al.   JOURNAL OF CLINICAL PATHOLOGY

Tumor-specific mutations in low-frequency genes affect their functional properties

(2015) Lale Erdem-Eraslan et al.   JOURNAL OF NEURO-ONCOLOGY

Mutational landscape and clonal architecture in grade II and III gliomas

(2015) Hiromichi Suzuki et al.   NATURE GENETICS

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial

(2015) Hendrikus J. Dubbink et al.   NEURO-ONCOLOGY

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

The genetic landscape of anaplastic astrocytoma

(2015) Patrick J. Killela et al.   Oncotarget

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

(2015) Patrick J. Killela et al.   Oncotarget

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma

(2014) David E. Reuss et al.   ACTA NEUROPATHOLOGICA

International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

(2014) David N. Louis et al.   BRAIN PATHOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

(2013) Benedikt Wiestler et al.   ACTA NEUROPATHOLOGICA

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Current clinical development of PI3K pathway inhibitors in glioblastoma

(2012) P. Y. Wen et al.   NEURO-ONCOLOGY

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

(2012) D. Singh et al.   SCIENCE

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

(2011) C. Bettegowda et al.   SCIENCE

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma

(2010) Lonneke A.M. Gravendeel et al.   HUMAN MUTATION

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

(2010) Nanne K Kloosterhof et al.   LANCET ONCOLOGY

The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma

(2010) L B C Bralten et al.   ONCOGENE

A syngeneic glioma model to assess the impact of neural progenitor target cell age on tumor malignancy

(2009) Andrei M. Mikheev et al.   AGING CELL

Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

(2009) L. A.M. Gravendeel et al.   CANCER RESEARCH

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Gli1 inhibition induces cell-cycle arrest and enhanced apoptosis in brain glioma cell lines

(2009) Ke Wang et al.   JOURNAL OF NEURO-ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE